Longevity Biotech

Longevity Biotech is developing an entirely new approach to therapeutics development via artificial protein technology (“Hybridtides”). Hybridtides® are peptide molecules that contain both α- and β-amino acid subunits, which makes them resistant to breakdown by natural digestive enzymes, tunable to very stable conformations, and able to mimic information-rich surfaces displayed by natural proteins or peptides, enabling new drug designs which are more stable and more clinically active.

Current work will establish the platform’s potential in a clinically important indication in cardiovascular disease, pulmonary arterial hypertension.



Management Team

Scott Shandler, CEO

Company HQ

Philadelphia, PA, US